Overview of Regulatory Environment
(India)
1. Regulatory Environment in India
- India
has a well-defined, multi-ministerial drug regulatory system.
- Regulation
of drugs, medical devices, biologics, and r-DNA products
is shared among different ministries.
- Central
and State authorities work together for approval, licensing,
quality control, and monitoring.
2. Central Regulatory Authority
CDSCO (Central Drugs Standard
Control Organization)
- Principal regulatory
body for:
- Drug
approval
- New
drug development
- Clinical
trials
- Import
& marketing authorization
- Functions
under:
- Ministry of Health
& Family Welfare (MoHFW)
3. State Regulatory Authorities
- State Drug Control
Organizations
- Issue
licenses for manufacture, sale, and distribution of
approved drugs
- Monitor
drug quality at state level
- Work
in coordination with CDSCO
India – Well Defined Drug Regulatory
System
A. Ministry of Health & Family
Welfare
Hierarchy:
- DGHS
(Directorate General of Health Services)
- CDSCO
- DCGI
(Drugs Controller General of India)
- DTAB
(Drugs Technical Advisory Board)
Key Functions:
- Approval
of new drugs
- Clinical
trial oversight
- Medical
devices regulation
- Pharmacovigilance
Divisions under CDSCO:
- Enforcement
& GMP Audit Division
- Quality
Control Division (CDTL)
- Registration
Division
- New
Drugs Division
- Pharmacovigilance
- Training
& Capacity Building
B. Ministry of Chemicals &
Fertilizers
Department of Pharmaceuticals
- Responsible
for pharmaceutical industry policy
- Oversees:
- NPPA (National
Pharmaceutical Pricing Authority)
NPPA Functions:
- Drug
price control
- Monitoring
prices of essential medicines
- Ensuring
availability of affordable drugs
C. Ministry of Commerce
Patent Office
- Handles:
- Drug
patents
- Intellectual
Property Rights (IPR)
Controller General of Patents
- Grants
patents for pharmaceuticals and biotechnology products
D. Ministry of Science &
Technology
Research & Innovation Bodies:
- ICMR
– Indian Council of Medical Research
- DBT
– Department of Biotechnology
- CSIR
Laboratories
Role:
- Biomedical
research
- Biotechnology
product development
- Support
for translational research
Key Teaching Takeaways (Exam Points)
- CDSCO
is the central drug regulatory authority in India.
- DCGI
is the head of CDSCO.
- Licensing
is mainly done by State Drug Authorities.
- Drug
pricing is controlled by NPPA, not CDSCO.
- Patents
fall under Ministry of Commerce, not Health.
- Research
bodies like ICMR & CSIR do not approve drugs but
support R&D.
REGULATORY BODIES IN INDIA
(Pharmaceutical & Biomedical)
a) Drugs Controller General of India
(DCGI)
- Head
of CDSCO
- Main authority for:
- Approval
of clinical trials
- Approval
of new drugs
- Regulation
of imported drugs
- Oversight
of biologics and medical devices
- Ensures
safety, efficacy, and quality standards
- Functions
under Ministry of Health & Family Welfare
📌 Exam note: DCGI is not a
separate organization, but the statutory head of CDSCO.
b) Indian Council of Medical
Research (ICMR)
- Apex
body for biomedical research in India
- Conducts
and promotes:
- Clinical
research
- Epidemiological
studies
- Public
health research
- Provides
ethical guidelines for biomedical and health research
📌 Exam note: ICMR does not
approve drugs; it supports research and ethics.
c) Drugs Consultative Committee
(DCC)
- Statutory
advisory body under Drugs & Cosmetics Act
- Provides
technical advice to:
- CDSCO
- Central
and State Governments
- Ensures
uniform implementation of the Drugs & Cosmetics Act
across states
d) Central Drugs Laboratory (CDL)
- National
reference laboratory
- Responsible
for:
- Quality control testing
of drugs
- Analysis
of samples referred by courts or regulators
- Supports
enforcement of drug quality standards
📌 Exam note: CDL is different from CDTL,
which works directly under CDSCO.
e) Central License Approving
Authority (CLAA)
- Grants
central approval for:
- Manufacturing
licenses of specified drugs
- Blood
products
- Vaccines
- Recombinant
DNA products
- Operates
through CDSCO in coordination with States
f) Drugs Technical Advisory Board
(DTAB)
- Highest
technical advisory body under Drugs & Cosmetics Act
- Advises
CDSCO on:
- Drug
standards
- Technical
amendments
- Regulatory
policies
📌 Exam tip: DTAB = technical,
DCC = coordination & uniformity
g) National Pharmaceutical Pricing
Authority (NPPA)
- Regulates
drug pricing
- Functions:
- Fixes
or revises prices of scheduled drugs
- Monitors
prices of non-scheduled (decontrolled) drugs
- Implements
Drug Price Control Orders (DPCO)
📌 Important correction:
NPPA does NOT approve drugs — it controls prices only.
h) Genetic Engineering Appraisal
Committee (GEAC)
(Earlier called Approval Committee; “Appraisal” is the correct term)
- Regulates
activities involving:
- Genetic
engineering
- GM
organisms
- r-DNA
products
- Biotech
clinical trials involving GM products are:
i) Department of Biotechnology (DBT)
- Functions
under Ministry of Science & Technology
- Promotes:
- Biotechnology
research
- Infrastructure
development
- Translational
research
- Funds
and supports biotech institutions and programs
📌 Exam note: DBT supports
development, not regulatory approvals.
j) Atomic Energy Regulatory Board
(AERB)
- Regulates:
- Radiation-emitting
equipment
- Nuclear
medicine devices
- Radiopharmaceutical
safety
- Ensures
radiation protection for workers and patients
QUICK EXAM SUMMARY TABLE
|
Body
|
Main
Role
|
|
DCGI
|
Drug & clinical trial approval
|
|
ICMR
|
Biomedical research & ethics
|
|
DCC
|
Uniform enforcement guidance
|
|
DTAB
|
Technical advisory
|
|
CDL
|
Drug quality testing
|
|
CLAA
|
Central manufacturing approval
|
|
NPPA
|
Drug price control
|
|
GEAC
|
Genetic engineering regulation
|
|
DBT
|
Biotechnology development
|
|
AERB
|
Radiation equipment regulation
|
k) Bhabha Atomic Research Centre
(BARC)
- Premier
research institution under the Department of
Atomic Energy (DAE).
- Involved
in:
- Research
and development of nuclear science
- Development
of radiopharmaceuticals
- Important clarification
(exam-relevant):
👉
BARC does NOT act as the regulatory approval authority.
👉
Regulatory control and approval of radiation equipment and
radiopharmaceutical use lie with AERB, not BARC.
📌 One-line exam answer:
BARC is a research and development body, while AERB is
the regulator.
CLINICAL RESEARCH REGULATIONS IN
INDIA
Drug Controller General of India
(DCGI)
- DCGI
functions under CDSCO
- CDSCO
works under the Ministry of Health & Family Welfare
- Enforces
the Drugs and Cosmetics Act, 1940 & Rules
Role of DCGI in Clinical Research
- Primary authority for
regulating clinical trials in India
- Responsible
for:
- Approval
of clinical trial protocols
- Approval
of new drugs
- Oversight
of safety, efficacy, and quality
- Coordinates
with:
- Ethics
Committees
- Other
regulatory bodies (e.g., GEAC for biotech products)
CDSCO – ORGANIZATIONAL STRUCTURE
Head:
➡️
Drugs Controller General of India (DCGI)
1. Headquarters
Functions:
- New
drug approval
- CLAA-related
approvals
- Import
registration
- Coordination
with DTAB & DCC
2. Zonal Offices (4)
Functions:
- GMP
audits
- Coordination
with State Drug Control Authorities
- Enforcement
activities
3. Sub-Zonal Offices (2)
Functions:
- GMP
inspections
- Sales
and distribution surveillance
4. Port Offices (7)
Functions:
- Control
of import & export of drugs
- Sampling
of imported products
5. Laboratories (6)
Functions:
- Testing
of drug samples
- Validation
of test protocols
- Quality
surveillance support
FUNCTIONS OF CDSCO (EXAM-IMPORTANT)
- Approval
of new drugs
- Approval
and regulation of clinical trials
- Import
registration and licensing
- Licensing
of:
- Blood
banks
- Large
Volume Parenterals (LVPs)
- Vaccines
- r-DNA
products
- Selected
medical devices
QUICK EXAM DIFFERENTIATION (Very
Important)
|
Body
|
Primary
Role
|
|
DCGI
|
Drug & clinical trial approval
|
|
CDSCO
|
Central drug regulatory authority
|
|
BARC
|
Nuclear & radiopharmaceutical
research
|
|
AERB
|
Radiation safety & regulatory
approval
|
|
GEAC
|
Genetic engineering & GM
products
|
|
NPPA
|
Drug price control
|
“DCGI approves the drug and the trial, GEAC clears genetic safety,
AERB clears radiation safety, and BARC supports research.”
FUNCTIONS UNDER DRUGS &
COSMETICS ACT AND RULES (India)
1. Amendment of Drugs and Cosmetics
Act & Rules
- Central
Government has the authority to:
- Amend
the Drugs and Cosmetics Act, 1940
- Amend
the Drugs and Cosmetics Rules, 1945
- Amendments
are done to:
- Incorporate
new technologies
- Harmonize
with global guidelines (ICH, WHO)
- Strengthen
patient safety and regulatory oversight
2. Banning of Drugs and Cosmetics
- Central
Government can prohibit manufacture, sale, or distribution
of drugs/cosmetics:
- If
found unsafe
- If
lacking therapeutic justification
- If
quality standards are not met
- Implemented
through Gazette notifications
3. Grant of Licenses & NOCs
- Test License
→ For manufacture/import of drugs for:
- Examination
- Test
- Analysis
- Personal License
→ For import of small quantities for personal use
- NOC for Export
→ Issued by CDSCO for export of drugs not marketed in India
4. Testing of Drugs
- Conducted
through:
- Central
Drugs Laboratory (CDL)
- CDTLs
and State Drug Testing Laboratories
- Purpose:
- Ensure
compliance with pharmacopeial standards
- Support
enforcement and legal proceedings
CLINICAL TRIAL GUIDELINES IN INDIA
Clinical trials in India are governed by the following regulatory and
ethical frameworks:
1. Schedule Y – Drugs &
Cosmetics Rules, 1945
- Core
legal framework for:
- Clinical
trials
- New
drug approval
- (Note:
Schedule Y is part of the Rules, not the Act)
2. Ethical Guidelines for Biomedical
Research on Human Participants
- Issued
by ICMR
- First
issued in 2000, later revised (2006, 2017)
- Covers:
- Informed
consent
- Ethics
committee functioning
- Participant
protection
3. Good Clinical Practice (GCP)
Guidelines
- Issued
by CDSCO
- Ensure:
- Ethical
conduct
- Scientific
validity
- Credibility
of clinical trial data
4. Good Laboratory Practice (GLP)
Guidelines
- Issued
by CDSCO / DBT
- Applicable
to:
- Non-clinical
safety studies
- Preclinical
toxicology studies
5. Bioavailability (BA) &
Bioequivalence (BE) Guidelines
- Issued
by CDSCO
- Mandatory
for:
- Generic
drug approval
- Fixed
dose combinations (FDCs)
6. National Pharmacovigilance
Programme
- Launched
in 2004
- Strengthened
later as PvPI (Pharmacovigilance Programme of India)
- Purpose:
- Detection
- Assessment
- Prevention
of adverse drug reactions
IMPORTANCE OF SCHEDULE Y
(HIGH-YIELD)
- Provides
regulatory requirements for:
- Import
of new drugs
- Manufacture
of new drugs
- Conduct
of clinical trials
- Defines:
- Phase
I–IV trials
- Study
design
- Data
requirements
- Harmonized
with:
📌 Exam line:
Schedule Y ensures that Indian clinical trials follow globally accepted
scientific and ethical standards.
RULES GOVERNING REGISTRATION OF
DRUGS IN INDIA
Rule 122A
- Permission
to import a new drug
Rule 122B
- Permission
to manufacture a new drug
Rule 122D
- Permission
to import or manufacture Fixed Dose Combinations (FDCs)
Rule 122DA
- Permission
to conduct clinical trials for new drugs
Rule 122E
- Defines
“New Drug” Includes:
- New
chemical entity
- New
indication
- New
dosage form
- New
route of administration
- New
FDC
APPLICATION FOR PERMISSION TO
CONDUCT CLINICAL TRIALS
IND Application
- Sponsor
must submit Form 44 to CDSCO
- Same
Form 44 is used for:
- Clinical
trial permission
- Import
of new drug
- Manufacture
of new drug
IND CONTENTS (As per Schedule Y)
1.
Chemical & Pharmaceutical
Information
- Drug
composition
- Stability
data
- Manufacturing
details
2.
Animal Pharmacology & Toxicology
Data
- Acute
toxicity
- Repeated
dose toxicity
- Reproductive
toxicity (if applicable)
3.
Clinical Trial Protocol
- Study
design
- Inclusion/exclusion
criteria
- Endpoints
4.
Investigator’s Brochure
5.
Ethics Committee approval
6.
Informed Consent Documents
📌 Conceptual link:
IND structure in India is similar to USFDA IND, but governed
under Schedule Y.
ONE-LINE EXAM SUMMARY
Clinical trials in India are regulated by Schedule Y,
approved by DCGI, ethically guided by ICMR,
and monitored through Pharmacovigilance Programme of India.
IND (Investigational New Drug)
APPLICATION – INDIA
Additional IND Contents (as shown)
- Animal toxicology data
- Regulatory status in
other countries (if available)
- Proposed Phase-I and
Phase-II clinical study plans
APPROVAL PROCESS OF IND (India)
Step-wise Flow:
- IND Applicant (Sponsor)
⬇️
submits application
- CDSCO – Headquarters
⬇️
- Examination by New Drugs
Division
⬇️
- Detailed review by IND
Committee / Subject Expert Committee (SEC)
⬇️
- Recommendation to DCGI
(Drugs Controller General of India)
⬇️
- Final Approval /
Rejection
📌 Teaching tip:
DCGI is the final decision-making authority, but decisions are
committee-based.
IND REVIEW TIMELINES (As per
traditional exam references)
|
Phase
|
Timeline
|
|
Phase I
|
90 days
|
|
Phase II
|
45 days
|
|
Phase III
|
60 days
|
⚠️ Important clarification for students:
- These
timelines are classical / exam-oriented values.
- Actual
timelines may vary under NDCTR 2019, but exams
still ask these numbers.
TYPES OF IND APPLICATIONS IN INDIA
CATEGORY – A (Abbreviated IND)
- Clinical
trial protocols already approved in:
- USA,
UK, Switzerland
- EU
(EMEA/EMA)
- Japan,
Australia, Canada
- Germany,
South Africa
- Known
as Abbreviated INDs
- Fast-track approval
- Approval
time: 3–4 weeks
📌 Concept: India relies on prior
international regulatory experience.
CATEGORY – B (Regular IND)
- Includes:
- All
trials not covered under Category-A
- Most Phase-I clinical
trials
- Requires
full scientific and regulatory review
- Approval
time: 8–12 weeks
📌 Concept: New molecules and
first-in-human studies fall here.
QUICK COMPARISON (HIGH-YIELD)
|
Feature
|
Category
A
|
Category
B
|
|
Prior foreign approval
|
Yes
|
No
|
|
Review type
|
Abbreviated
|
Full review
|
|
Phase-I trials
|
Rare
|
Common
|
|
Approval time
|
3–4 weeks
|
8–12 weeks
|
ONE-LINE EXAM ANSWERS
- IND approval in India
is granted by DCGI through CDSCO.
- Category-A INDs
are fast-tracked based on prior global approvals.
- Category-B INDs
undergo full regulatory scrutiny.
“India follows a risk-based IND review system—less review
when global data exists, and deeper review for new or first-in-human drugs.”
CLINICAL TRIAL REQUIREMENTS (INDIA)
1. New Drugs Discovered in India
- Clinical
trials must be conducted from Phase-I to Phase-III in
India.
- Full
evaluation of:
- Safety
- Efficacy
- Dose
optimization
📌 Reason: No prior human data exists.
2. New Drugs Discovered Outside
India
- Phase-I trials are
generally not required in India
- Because
Phase-I data is already available from abroad
- Exception:
Phase-I may be allowed if the drug is of special relevance to
Indian public health.
3. Acceptance of Foreign Clinical
Data
- Safety
and efficacy data from other countries may be accepted
when:
- Drug
is intended for serious or life-threatening diseases
- Indian
population relevance is justified
- Bridging
studies may still be required.
4. Relaxation of Data Requirements
For drugs indicated for:
- Life-threatening
diseases
- Serious
illnesses
- Diseases
of special relevance to Indian health scenario
➡️ Toxicological and clinical data
requirements may be:
- Abbreviated
- Deferred
- Omitted
(in exceptional cases)
📌 Examples: Cancer, HIV, TB, rare
diseases, pandemics.
ONE-LINE EXAM SUMMARY (INDIA)
India follows a risk-based and public-health-oriented clinical trial
approach, allowing flexibility for serious and life-threatening
diseases.
DRUG REGULATORY AGENCY IN USA
U.S. FOOD AND DRUG ADMINISTRATION
(USFDA)
Nature of FDA
- A
scientific, regulatory, and public health agency
- Operates
under the Department of Health and Human Services (HHS)
FDA Regulatory Responsibilities
Regulates safety and effectiveness of:
- Human
drugs
- Animal
drugs
- Biologics
- Medical
devices
- Radiation-emitting
products
- Food
and color additives
- Infant
formulas
- Cosmetics
- Animal
feed
Scientific Role of FDA
- FDA
scientists evaluate:
- New
drug applications
- Biologics
- Complex
medical devices
- Food
& color additives
- Animal
drugs
Scope of FDA Oversight
- Monitors:
- Manufacturing
- Import
- Transport
- Storage
- Sale
- Covers
products worth ~$1 trillion annually
FDA Leadership
- Headed
by the Commissioner of Food and Drugs
- Appointed
by:
- President of the United
States
- Confirmed
by the Senate
CLINICAL RESEARCH REGULATIONS IN USA
NEW DRUG APPROVAL PROCESS (FDA)
1. Pre-IND Meeting
- Informal
discussion between Sponsor and FDA
- Purpose:
- Clarify
regulatory expectations
- Discuss
preclinical data
- Plan
clinical development
2. Submission of IND
- Sponsor
submits Investigational New Drug (IND) application
- FDA
reviews:
- Preclinical
safety data
- Clinical
trial protocol
- Investigator
information
3. End-of-Phase-II Meeting
- Critical
decision-making stage
- Purpose:
- Review
Phase-II data
- Agree
on Phase-III design
- Reduce
chances of failure in later stages
4) Accelerated Drug Review
- Applied
for drugs intended to:
- Treat serious
or life-threatening diseases
- Address
unmet medical needs
- Based
on:
- Surrogate
endpoints
- Early
clinical benefit
5) Parallel Track
- Allows early
access to investigational drugs for:
- Patients
with serious diseases
- Those
who cannot enroll in clinical trials
- Commonly
used in:
6) Clinical Hold Decision
- FDA may
temporarily suspend or delay a clinical trial if:
- Safety
concerns arise
- Insufficient
information is provided
- Protocol
deficiencies exist
📌 Exam line:
Clinical hold protects patient safety.
7) Notification to Sponsor
- FDA
communicates:
- Deficiencies
- Required
clarifications
- Additional
data needs
- Sponsor
must respond before proceeding further.
8) Sponsor / FDA Meetings (Pre-NDA)
- Conducted
before NDA submission
- Purpose:
- Confirm
completeness of data
- Discuss
NDA format and content
- Reduce
chances of rejection
9) New Drug Application (NDA)
- Formal
request for marketing approval
- NDA
contains:
- Preclinical
data
- Clinical
trial results
- Manufacturing
details
- Labeling
information
10) Final Meetings with Sponsor
- FDA
discusses:
- Remaining
issues
- Risk–benefit
assessment
- Labeling
and post-marketing commitments
11) Permission for Marketing
- FDA
grants approval if:
- Drug
is safe and effective
- Manufacturing
complies with cGMP
- Drug
can now be marketed in the USA
12) Post-Marketing Review (Phase-IV)
- Continuous
monitoring for:
- Adverse
drug reactions
- Rare
or long-term effects
- Includes:
- Pharmacovigilance
- Risk
management plans
NEW DRUG DEVELOPMENT TIMELINE (USA)
1. Pre-Clinical Research
- Duration:
1–2 years
- Includes:
- In-vitro
studies
- Animal
testing
- Initial
synthesis & purification
2. Clinical Research &
Development
- Duration:
Up to ~10 years
- Phases:
- Phase I
– Safety, dose (healthy volunteers)
- Phase II
– Efficacy, dose optimization
- Phase III
– Large-scale confirmation
📌 IND undergoes 30-day
safety review before human trials begin.
3. NDA Review
- Average
duration: ~24 months
- Can
range from 2 months to 7 years
- FDA
evaluates:
- Benefit–risk
profile
- Manufacturing
quality
- Labeling
accuracy
4. Post-Marketing Surveillance
- Includes:
- Adverse
event reporting
- Surveys
- Sampling
& testing
- Inspections
REGULATORY ENVIRONMENT IN EUROPE
Regulatory Authority – Europe
European Medicines Agency (EMA)
(Earlier called EMEA – European Medicines
Evaluation Agency)
📌 Correct current
term: EMA
Role of EMA
- Central
regulatory authority for medicines in the European Union
- Responsible
for:
- Scientific
evaluation
- Supervision
- Safety
monitoring of medicines
EMA & Clinical Trials
- Relies
on:
- Results
of clinical trials conducted by pharmaceutical companies
- Provides
scientific opinions on:
- Authorization
of medicines
- Final
approval granted by:
ONE-LINE EXAM COMPARISON
|
Region
|
Authority
|
Approval
Focus
|
|
India
|
DCGI / CDSCO
|
Public health–based flexibility
|
|
USA
|
FDA
|
Step-wise scientific rigor
|
|
Europe
|
EMA
|
Centralized EU authorization
|
TEACHING CLOSURE LINE
“Drug approval is a global, multi-stage
scientific process—FDA focuses on structured rigor, EMA on centralized
EU evaluation, and India on public-health-driven flexibility.”
REGULATORY ENVIRONMENT IN EUROPE –
CLINICAL TRIALS & MARKETING AUTHORISATION
Role of the European Medicines
Agency (EMA)
- Authorization of
clinical trials is granted at the Member
State level (National Competent Authorities).
- However,
EMA plays a key coordinating role by:
- Ensuring
uniform application of Good Clinical Practice (GCP)
across the European Economic Area (EEA)
- Working
in cooperation with Member States
- EMA
manages the EU clinical trials database
- Current system:
CTIS (Clinical Trials Information System)
(Older exams may still mention “EU Clinical Trials Database”)
📌 Exam note:
Clinical trial approval = national level,
Clinical trial standards & oversight = EMA coordination.
EUROPEAN MEDICINES AGENCY (EMA)
(Earlier called EMEA – European Medicines
Evaluation Agency)
- Decentralized agency of
the European Union
- Current headquarters:
Amsterdam, Netherlands
⚠️
London is no longer correct (post-Brexit)
MARKETING AUTHORISATION OF MEDICINES
IN THE EU
Medicines in the European Union can be authorised
through:
- Centralized
Authorisation Procedure
- National / Decentralised
/ Mutual Recognition Procedures
CENTRALIZED AUTHORISATION PROCEDURE
(Community Authorisation Procedure)
- Results
in a single marketing authorisation
- Valid
in:
- All EU
Member States
- EEA countries:
Iceland, Liechtenstein, Norway
📌 Term:
This authorisation is called a Community Marketing Authorisation.
MEDICINES FOR WHICH CENTRALIZED
PROCEDURE IS COMPULSORY
1) Biotechnology-derived medicines
- Products
obtained by:
- Genetic
engineering
- Recombinant
DNA technology
- Hybridoma
technology
2) Medicines intended for treatment
of:
- HIV /
AIDS
- Cancer
- Diabetes
- Neurodegenerative
disorders
- Autoimmune
diseases & immune dysfunctions
3) Orphan Medicines
- Medicines
for rare diseases
- Officially
designated as orphan drugs
📌 Exam line:
Centralized procedure is mandatory for biotech and orphan
medicines.
OPTIONAL USE OF CENTRALIZED
PROCEDURE
For medicines not falling under the mandatory
scope, companies may still apply via the centralized route if:
- The
medicine represents:
- Significant
therapeutic innovation
- Scientific
or technical advancement
- Or if
authorization is:
- In the
interest of public health
APPLICATION & EVALUATION PROCESS
(CENTRALIZED PROCEDURE)
- Application
is submitted directly to EMA
- Evaluation
performed by EMA’s Scientific Committees
(mainly CHMP – Committee for Medicinal Products for Human Use)
Evaluation Timeline
- Maximum: 210 days
- (Clock
stops may occur when additional data is requested)
FINAL AUTHORISATION
- EMA
issues a scientific opinion
- Opinion
is forwarded to the European Commission
- European Commission
grants the final marketing authorisation
📌 Exam point:
EMA → Scientific opinion
European Commission → Legal approval
POST-AUTHORISATION
- Once a Community
Marketing Authorisation is granted:
- Marketing
authorisation holder can:
- Market
the medicine
- Supply
it to patients and healthcare professionals
- Valid
across all EU/EEA countries
ONE-PAGE EXAM SUMMARY
|
Aspect
|
Key
Point
|
|
Clinical trial approval
|
Member States
|
|
GCP harmonization
|
EMA
|
|
EU trial database
|
CTIS
|
|
Centralized approval
|
EMA + European Commission
|
|
Timeline
|
210 days
|
|
Validity
|
EU + EEA
|
|
HQ of EMA
|
Amsterdam
|
TEACHING CLOSURE LINE
“In Europe, Member States authorize trials,
EMA harmonizes standards, and the European Commission
grants marketing approval.”
NATIONAL AUTHORISATION PROCEDURES
(EU)
- Each EU
Member State has its own national procedure for
authorising medicinal products outside the scope of the
centralized procedure.
- These
authorisations are valid only within that Member State’s territory.
- Information
on national procedures is available on:
- Websites
of the National Competent Authorities (NCAs)
- Heads of Medicines
Agencies (HMA) website (useful central entry
point)
ROUTES FOR AUTHORISATION IN MULTIPLE
EU COUNTRIES
(For products outside mandatory centralized
scope)
(A) DECENTRALISED PROCEDURE (DCP)
- Used
when:
- The
medicinal product has not yet been authorised in any EU Member
State
- The
product does not fall under mandatory centralized procedure
- Companies
apply simultaneously to multiple EU countries.
- One
country acts as:
- Reference Member State
(RMS)
- Other
participating countries are:
- Concerned Member States
(CMS)
📌 Key exam line:
DCP = Simultaneous first-time authorisation in multiple EU countries
(B) MUTUAL RECOGNITION PROCEDURE
(MRP)
- Used
when:
- A
medicine is already authorised in one EU Member State
- That
country becomes the:
- Reference Member State
(RMS)
- Other
EU countries:
- Recognise the existing
national authorisation
- Leads
to national marketing authorisations in additional
countries.
📌 Key exam line:
MRP = First national approval → then recognition by other states
QUICK COMPARISON: DCP vs MRP
|
Feature
|
DCP
|
MRP
|
|
Prior authorisation
|
❌
No
|
✅
Yes (one country)
|
|
First approval
|
Simultaneous
|
National first
|
|
RMS involved
|
Yes
|
Yes
|
|
Centralized mandatory?
|
No
|
No
|
GOOD CLINICAL PRACTICE (GCP) – HUMAN
MEDICINAL PRODUCTS
Legal Framework (UPDATED)
- Requirements
for clinical trials in the EU were originally implemented
through:
- Clinical Trials
Directive (2001/20/EC) ⚠️
now repealed
- Current governing law:
- EU Clinical Trials
Regulation (EU) No. 536/2014
- Applies
across the European Economic Area (EEA).
📌 Exam tip:
Directive = old
Regulation 536/2014 = current and directly applicable
GCP REQUIREMENTS
- All
clinical trials included in marketing authorisation applications
in the EEA must:
- Be
conducted in accordance with Good Clinical Practice (GCP)
- GMP requirements
apply to:
- Investigational
Medicinal Products (IMPs)
- Inspections
are conducted to verify compliance with:
- GCP
- GMP
(for clinical trials)
VOLUME 10 – EU RULES FOR CLINICAL
TRIALS
- Volume 10
of The Rules Governing Medicinal Products in the EU covers:
- Clinical
trial authorisation
- Safety
reporting
- GCP
inspections
- GCP
and GMP requirements
- Applies
to trials conducted in the EEA
ICH GCP ADOPTION IN EUROPE
- Europe
adopted ICH-GCP (E6) in July 1996
- ICH-GCP
is:
- Binding
for clinical trials used in EU regulatory submissions
- Published
and maintained through EMA resources
📌 Common MCQ:
ICH-GCP adopted in Europe → 1996
GCP INSPECTORS WORKING GROUP (EMA)
- EMA
relies on Member State GCP inspectors for:
- Inspection
planning
- Conduct
- Reporting
- Coordination
is achieved through the:
- GCP Inspectors Working
Group
Composition & Meetings
- Members:
- GCP
inspectors from EEA Member States
- Observers
from:
- Candidate
countries
- Switzerland
- Meetings:
- Regularly (typically 4
times per year)
- Held
at EMA (Amsterdam)
ROLE OF GCP INSPECTORS WORKING GROUP
- Develops
harmonised procedures for:
- Coordination
of inspections
- Preparation
and conduct of inspections
- Reporting
of inspection outcomes
- Especially
important for:
- Centralized marketing
authorisation procedure
EXAM-READY SUMMARY (VERY IMPORTANT)
- National
authorisation → Single country
- DCP → Simultaneous
first approval in multiple countries
- MRP → Recognition
of existing national approval
- GCP
legal basis → EU Regulation 536/2014
- ICH-GCP
adopted → 1996
- GCP
inspections → Coordinated by EMA via inspectors working group
ONE-LINE MEMORY AID
Centralized = EMA + Commission
DCP = parallel first approvals
MRP = recognise existing approval
